- Home
- SUUN vs IMUX Comparison
SUUN vs IMUX Comparison
Compare SUUN & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUUN
- IMUX
- Stock Information
- Founded
- SUUN 2013
- IMUX 2016
- Country
- SUUN Canada
- IMUX United States
- Employees
- SUUN N/A
- IMUX N/A
- Industry
- SUUN
- IMUX Biotechnology: Pharmaceutical Preparations
- Sector
- SUUN
- IMUX Health Care
- Exchange
- SUUN Nasdaq
- IMUX Nasdaq
- Market Cap
- SUUN 123.9M
- IMUX 100.0M
- IPO Year
- SUUN N/A
- IMUX N/A
- Fundamental
- Price
- SUUN $2.75
- IMUX $1.10
- Analyst Decision
- SUUN
- IMUX Strong Buy
- Analyst Count
- SUUN 0
- IMUX 5
- Target Price
- SUUN N/A
- IMUX $13.20
- AVG Volume (30 Days)
- SUUN 35.8K
- IMUX 900.0K
- Earning Date
- SUUN 11-14-2024
- IMUX 11-07-2024
- Dividend Yield
- SUUN N/A
- IMUX N/A
- EPS Growth
- SUUN N/A
- IMUX N/A
- EPS
- SUUN N/A
- IMUX N/A
- Revenue
- SUUN $49,373,547.00
- IMUX N/A
- Revenue This Year
- SUUN N/A
- IMUX N/A
- Revenue Next Year
- SUUN N/A
- IMUX N/A
- P/E Ratio
- SUUN N/A
- IMUX N/A
- Revenue Growth
- SUUN 223.82
- IMUX N/A
- 52 Week Low
- SUUN $2.51
- IMUX $0.97
- 52 Week High
- SUUN $7.50
- IMUX $2.11
- Technical
- Relative Strength Index (RSI)
- SUUN 37.64
- IMUX 36.18
- Support Level
- SUUN $2.57
- IMUX $1.02
- Resistance Level
- SUUN $3.06
- IMUX $1.13
- Average True Range (ATR)
- SUUN 0.23
- IMUX 0.08
- MACD
- SUUN 0.01
- IMUX 0.00
- Stochastic Oscillator
- SUUN 27.29
- IMUX 31.37
About SUUN SolarBank Corporation Common Stock
SolarBank Corp is an independent renewable and clean energy project developer and asset operator based in Canada and the United States. It is engaged in the development and operation of solar photovoltaic power generation projects in the province of Ontario and the state of New York. The company operates in two principal geographical areas - Canada and United States with a substantial portion of its overall revenue being generated from United States.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.